Literature DB >> 6502368

IgA antigliadin antibodies in celiac and inflammatory bowel disease.

C R Koninckx, J P Giliams, I Polanco, A S Peña.   

Abstract

Antibodies against gliadin of the IgA class were assessed with an enzyme-linked immunosorbent assay technique in children with celiac disease, healthy blood donors, and adult patients with active Crohn's disease or ulcerative colitis. Significantly higher antibody values were found in celiac children during gluten challenge and during the first 3 months on a gluten-free diet, compared with the findings in the healthy blood donors. The patients with active Crohn's disease had significantly higher levels of IgA antibodies to gliadin than the controls did. Although the highest values were found in patients with celiac disease on a gluten-containing diet, the difference between the means of these two groups was not statistically significant. No correlation was found between disease activity in ulcerative colitis and antibody values. The present results support the view that high levels of IgA-class antibodies against gliadin are indicative of small intestinal disease, especially celiac disease. The variability of the levels of antibodies found among the patients suggests that not only the amount of gluten in the diet but also other factors are important.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502368     DOI: 10.1097/00005176-198411000-00006

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  10 in total

1.  Jejunal immunoglobulin and antigliadin antibody secretion in adult coeliac disease.

Authors:  J F Colombel; F Mascart-Lemone; J Nemeth; J P Vaerman; C Dive; J C Rambaud
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

2.  Clinical application of immunological markers as monitoring tests in celiac disease.

Authors:  M Fotoulaki; S Nousia-Arvanitakis; P Augoustidou-Savvopoulou; F Kanakoudi-Tsakalides; T Zaramboukas; J Vlachonikolis
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

3.  Serological markers to differentiate between ulcerative colitis and Crohn's disease.

Authors:  M Oudkerk Pool; G Bouma; S G Meuwissen; B M von Blomberg; J P van de Merwe; W L Devillé; J C Fonk; A S Peña
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

4.  Anti-gliadin antibodies in breast milk from celiac mothers on a gluten-free diet.

Authors:  María Roca; Sabine Lisa Vriezinga; Paula Crespo-Escobar; Renata Auricchio; David Hervás; Gemma Castillejo; Maria Carmen Mena; Isabel Polanco; Riccardo Troncone; Maria Luisa Mearin; Carmen Ribes-Koninckx
Journal:  Eur J Nutr       Date:  2017-05-29       Impact factor: 5.614

5.  Prevalence and diagnostic significance of gliadin antibodies in children with Down syndrome.

Authors:  W Storm
Journal:  Eur J Pediatr       Date:  1990-09       Impact factor: 3.183

6.  Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin.

Authors:  M ten Dam; Y Van De Wal; M L Mearin; Y Kooy; S Peña; J W Drijfhout; F Koning; M Van Tol
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study.

Authors:  A Bürgin-Wolff; R Berger; H Gaze; H Huber; M J Lentze; D Nusslé
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

8.  Antigliadin and antiendomysium antibody determination for coeliac disease.

Authors:  A Bürgin-Wolff; H Gaze; F Hadziselimovic; H Huber; M J Lentze; D Nusslé; C Reymond-Berthet
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

Review 9.  Assessing of Celiac Disease and Nonceliac Gluten Sensitivity.

Authors:  N Ontiveros; M Y Hardy; F Cabrera-Chavez
Journal:  Gastroenterol Res Pract       Date:  2015-04-29       Impact factor: 2.260

10.  The intestinal B-cell response in celiac disease.

Authors:  Luka Mesin; Ludvig M Sollid; Roberto Di Niro
Journal:  Front Immunol       Date:  2012-10-04       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.